Transportability to the European population of Efficacy of Belumosudil as Compared with Physician’s Choice of Best Available Therapy for The Treatment of Chronic Graft Versus Host Disease
In line with positive efficacy results observed in previous real-world evidence studies in US and European patients, findings from this transportability analysis indicate that the treatment-response pattern are similar in Europe compared to US and cGVHD patients treated with belumosudil would have significantly more clinical benefit compared to BAT in Europe.
Authors
- Aleksandr Lazaryan (ORCID: https://orcid.org/0000-0001-9605-6436)
- Alexandra Koumas (ORCID: https://orcid.org/0000-0003-3680-306X)
- Shaum Kabadi (ORCID: https://orcid.org/0000-0002-9945-6491)
- E. K. Waller
- Susan Gruber (ORCID: https://orcid.org/0000-0003-0127-0099)
- Lauren Rota
- Ekaterina Ponomareva (ORCID: https://orcid.org/0000-0002-6334-8034)
- Aaron C. Logan (ORCID: https://orcid.org/0000-0002-1179-5879)
- Charlie Nicholls
- Mark van der Laan
- Enkeleida Nikai
- Daniel Wolff
- David Michonneau
- Catherine J. Lee
- Francesca Bonifazi
- Irfan Khan
- Carlos Solano
- Varun Mehra
- Kevin Hall
Institutions
- Emory Healthcare (US)
- Seattle Cancer Care Alliance (US)
- Emory University (US)
- Universitat de València (ES)
- Sanofi (France) (FR)
- Moffitt Cancer Center (US)
- University Hospital Regensburg (DE)
- Hospital Clínico Universitario de Valencia (ES)
- Piedmont Cancer Institute (US)
- Revolution Medicines (United States) (US)
- American Energy Technologies Co (United States) (US)
- Sanofi (United States) (US)
- Azienda USL di Bologna (IT)
- Hôpital Saint-Louis (FR)
- Sanofi (United Kingdom) (GB)
- King's College Hospital (GB)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.jtct.2026.03.028
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00